Zinc and Cancer: Implications for LIV-1 in Breast Cancer

Nutrients

Volumn 4, Issue 7, 2012, Pages 648-675

  Grattan, Bruce J ^a   Freake, Hedley C ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Cancer; LIV 1; Zinc; Zinc transporters; ZIP6

Indexed keywords

TRACE ELEMENT; UNCLASSIFIED DRUG; ZINC; ZINC TRANSPORTER; ZINC TRANSPORTER LIV 1; ZINC TRANSPORTER ZIP6;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; ION TRANSPORT; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ZINC TRANSPORT;

EID: 84864341746     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu4070648     Document Type: Review

References (207)

1. Vallee, B.L.; Falchuk, K.H. The biochemical basis of zinc physiology. Physiol. Rev. 1993, 73, 79-118.
2. Stipanuk, B.L.; Falchuk, K.H. Biochemical, Physiological, Molecular Aspects of Human Nutrition, 2nd ed.; Saunders/Elsevier: St. Louis, MO, USA, 1993; pp. 1044-1064.
3. Keilin, D.; Mann, T. Carbonic anhydrase. Purification and nature of the enzyme. Biochem. J. 1940, 34, 1163-1176.
4. Ho, E.; Ames, B.N. Low intracellular zinc induces oxidative DNA damage, disrupts p53, NFkappa B, and AP1 DNA binding, and affects DNA repair in a rat glioma cell line. Proc. Natl. Acad. Sci. USA 2002, 99, 16770-16775.
5. Choi, D.W.; Koh, J.Y. Zinc and brain injury. Annu. Rev. Neurosci. 1998, 21, 347-375.
6. Fuwa, K.; Wacker, W.E.; Druyan, R.; Bartholomay, A.F.; Vallee, B.L. Nucleic Acids and Metals, II: Transition Metals as Determinants of the Conformation of Ribonucleic Acids. Proc. Natl. Acad. Sci. USA 1960, 46, 1298-1307.
7. Shin, Y.A.; Eichhorn, G.L. Interactions of metal ions with polynucleotides and related compounds. XI. The reversible unwinding and rewinding of deoxyribonucleic acid by zinc(II) Ions through temperature manipulation. Biochemistry 1968, 7, 1026-1032.
8. Paski, S.C.; Xu, Z. Labile intracellular zinc is associated with 3T3 cell growth. J. Nutr. Biochem. 2001, 12, 655-661.
9. Fujii, T. Presence of zinc in nucleoli and its possible role in mitosis. Nature 1954, 174, 1108-1109.
10. Lodish, H.; Berk, A.; Matsudaira, P. Molecular Cell Biology, 5th ed.; W.H. Freeman and Company: New York, NY, USA, 2004; p. 386.
11. Spelsberg, T.C.; Rories, C.; Rejman, J.J.; Goldberger, A.; Fink, K.; Lau, C.K.; Colvard, D.S.; Wiseman, G. Steroid action on gene expression: Possible roles of regulatory genes and nuclear acceptor sites. Biol. Reprod. 1989, 40, 54-69.
12. Andreini, C.; Banci, L.; Bertini, I.; Rosato, A. Counting the zinc-proteins encoded in the human genome. J. Proteome Res. 2006, 5, 196-201.
13. Sekler, I.; Sensi, S.L.; Hershfinkel, M.; Silverman, W.F. Mechanism and regulation of cellular zinc transport. Mol. Med. 2007, 13, 337-343.
14. Fosmire, G.J. Zinc toxicity. Am. J. Clin. Nutr. 1990, 51, 225-227.
15. Gaither, L.A.; Eide, D.J. Eukaryotic zinc transporters and their regulation. Biometals 2001, 14, 251-270.
16. Eide, D.J. The SLC39 family of metal ion transporters. Pflugers Arch. 2004, 447, 796-800.
17. Milon, B.; Wu, Q.; Zou, J.; Costello, L.C.; Franklin, R.B. Histidine residues in the region between transmembrane domains III and IV of hZip1 are required for zinc transport across the plasma membrane in PC-3 cells. Biochim. Biophys. Acta 2006, 1758, 1696-1701.
18. Kagara, N.; Tanaka, N.; Noguchi, S.; Hirano, T. Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci. 2007, 98, 692-697.
19. Maret, W. Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid. Redox Signal. 2006, 8, 1419-1441.
20. Wakimoto, P.; Block, G. Dietary intake, dietary patterns, and changes with age: An epidemiological perspective. J. Gerontol. 2001, 56, 65-80.
21. Ames, B.N.; Wakimoto, P. Are vitamin and mineral deficiencies a major cancer risk? Nat. Rev. Cancer 2002, 2, 694-704.
22. Caulfield, L.E.; Zavaleta, N.; Shankar, A.H.; Merialdi, M. Potential contribution of maternal zinc supplementation during pregnancy to maternal and child survival. Am. J. Clin. Nutr. 1998, 68, 499S-508S.
23. Brown, K.H.; Peerson, J.M.; Rivera, J.; Allen, L.H. Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2002, 75, 1062-1071.
24. Wuehler, S.E.; Peerson, J.M.; Brown, K.H. Use of national food balance data to estimate the adequacy of zinc in national food supplies: Methodology and regional estimates. Public Health Nutr. 2005, 8, 812-819.
25. Lee, D.H.; Anderson, K.E.; Harnack, L.J.; Folsom, A.R.; Jacobs, D.R., Jr. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women's Health Study. J. Natl. Cancer Inst. 2004, 96, 403-407.
26. Willett, W.C. Diet, nutrition, and avoidable cancer. Environ. Health Perspect. 1995, 103, S165-S170.
27. Hankinson, S.E.; Colditz, G.A.; Willett, W.C. Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004, 6, 213-218.
28. Greenlee, H.; White, E.; Patterson, R.E.; Kristal, A.R. Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J. Altern. Complement. Med. (N.Y.) 2004, 10, 660-666.
29. Messina, M.; Hilakivi-Clarke, L. Early intake appears to be the key to the proposed protective effects of soy intake against breast cancer. Nutr. Cancer 2009, 61, 792-798.
30. Shu, X.O.; Zheng, Y.; Cai, H.; Gu, K.; Chen, Z.; Zheng, W.; Lu, W. Soy food intake and breast cancer survival. JAMA 2009, 302, 2437-2443.
31. Prasad, A.S.; Beck, F.W.; Endre, L.; Handschu, W.; Kukuruga, M.; Kumar, G. Zinc deficiency affects cell cycle and deoxythymidine kinase gene expression in HUT-78 cells. J. Lab. Clin. Med. 1996, 128, 51-60.
32. Paski, S.C.; Xu, Z. Growth factor stimulated cell proliferation is accompanied by an elevated labile intracellular pool of zinc in 3T3 cells. Can. J. Physiol. Pharmacol. 2002, 80, 790-795.
33. DeWys, W.; Pories, W. Inhibition of a spectrum of animal tumors by dietary zinc deficiency. J. Natl. Cancer Inst. 1972, 48, 375-381.
34. Takeda, A.; Goto, K.; Okada, S. Zinc depletion suppresses tumor growth in mice. Biol. Trace Elem. Res. 1997, 59, 23-29.
35. McQuitty, J.T., Jr.; DeWys, W.D.; Monaco, L.; Strain, W.H.; Rob, C.G.; Apgar, J.; Pories, W.J. Inhibition of tumor growth by dietary zinc deficiency. Cancer Res. 1970, 30, 1387-1390.
36. Dutta, A.; Schaller, M.; Franco, A.T.; Sankavaram, K.; Grattan, B.J.; Freake, H.C. Zinc retention differs between primary and transformed cells in response to zinc deprivation. J. Nutr. Biochem. 2010, 21, 162-170.
37. Sankavaram, K.; Freake, H.C. The effects of transformation and ZnT-1 silencing on zinc homeostasis in cultured cells. J. Nutr. Biochem. 2012, 23, 629-634.
38. Mills, B.J.; Broghamer, W.L.; Higgins, P.J.; Lindeman, R.D. Inhibition of tumor growth by zinc depletion of rats. J. Nutr. 1984, 114, 746-752.
39. Pories, W.J.; DeWys, W.D.; Flynn, A.; Mansour, E.G.; Strain, W.H. Implications of the inhibition of animal tumors by dietary zinc deficiency. Adv. Exp. Med. Biol. 1977, 91, 243-257.
40. DeWys, W.; Pories, W.J.; Richter, M.C.; Strain, W.H. Inhibition of Walker 256 carcinosarcoma growth of dietary zinc deficiency. Proc. Soc. Exp. Biol. Med. 1970, 135, 17-22.
41. Gurusamy, K.; Davidson, B.R. Trace element concentration in metastatic liver disease: A systematic review. J. Trace Elem. Med. Biol. 2007, 21, 169-177.
42. Gupta, S.K.; Singh, S.P.; Shukla, V.K. Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder. J. Surg. Oncol. 2005, 91, 204-208.
43. Zaichick, V.; Sviridova, T.V.; Zaichick, S.V. Zinc in the human prostate gland: Normal, hyperplastic and cancerous. Int. Urol. Nephrol. 1997, 29, 565-574.
44. Henshall, S.M.; Afar, D.E.; Rasiah, K.K.; Horvath, L.G.; Gish, K.; Caras, I.; Ramakrishnan, V.; Wong, M.; Jeffry, U.; Kench, J.G.; et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003, 22, 6005-6012.
45. Diez, M.; Arroyo, M.; Cerdan, F.J.; Munoz, M.; Martin, M.A.; Balibrea, J.L. Serum and tissue trace metal levels in lung cancer. Oncology 1989, 46, 230-234.
46. Cunzhi, H.; Jiexian, J.; Xianwen, Z.; Jingang, G.; Shumin, Z.; Lili, D. Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma. Biol. Trace Elem. Res. 2003, 94, 113-122.
47. Franklin, R.B.; Feng, P.; Milon, B.; Desouki, M.M.; Singh, K.K.; Kajdacsy-Balla, A.; Bagasra, O.; Costello, L.C. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer 2005, 4, 32.
48. Liang, J.Y.; Liu, Y.Y.; Zou, J.; Franklin, R.B.; Costello, L.C.; Feng, P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999, 40, 200-207.
49. Chakravarty, P.K.; Ghosh, A.; Chowdhury, J.R. Zinc in human malignancies. Neoplasma 1986, 33, 85-90.
50. Mulay, I.L.; Roy, R.; Knox, B.E.; Suhr, N.H.; Delaney, W.E. Trace-metal analysis of cancerous and noncancerous human tissues. J. Natl. Cancer Inst. 1971, 47, 1-13.
51. Margalioth, E.J.; Schenker, J.G.; Chevion, M. Copper and zinc levels in normal and malignant tissues. Cancer 1983, 52, 868-872.
52. Cui, Y.; Vogt, S.; Olson, N.; Glass, A.G.; Rohan, T.E. Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1682-1685.
53. Feng, P.; Li, T.L.; Guan, Z.X.; Franklin, R.B.; Costello, L.C. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002, 52, 311-318.
54. Li, M.; Zhang, Y.; Liu, Z.; Bharadwaj, U.; Wang, H.; Wang, X.; Zhang, S.; Liuzzi, J.P.; Chang, S.M.; Cousins, R.J.; et al. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc. Natl. Acad. Sci. USA 2007, 104, 18636-18641.
55. El-Tanani, M.K.; Green, C.D. Oestrogen-induced genes, pLIV-1 and pS2, respond divergently to other steroid hormones in MCF-7 cells. Mol. Cell. Endocrinol. 1995, 111, 75-81.
56. Taylor, K.M.; Morgan, H.E.; Johnson, A.; Hadley, L.J.; Nicholson, R.I. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem. J. 2003, 375, 51-59.
57. Unno, J.; Satoh, K.; Hirota, M.; Kanno, A.; Hamada, S.; Ito, H.; Masamune, A.; Tsukamoto, N.; Motoi, F.; Egawa, S.; et al. LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. Int. J. Oncol. 2009, 35, 813-821.
58. Zhao, L.; Chen, W.; Taylor, K.M.; Cai, B.; Li, X. LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway. Biochem. Biophys. Res. Commun. 2007, 363, 82-88.
59. Lue, H.W.; Yang, X.; Wang, R.; Qian, W.; Xu, R.Z.; Lyles, R.; Osunkoya, A.O.; Zhou, B.P.; Vessella, R.L.; Zayzafoon, M.; et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One 2011, 6, e27720.
60. Langmade, S.J.; Ravindra, R.; Daniels, P.J.; Andrews, G.K. The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J. Biol. Chem. 2000, 275, 34803-34809.
61. Liuzzi, J.P.; Blanchard, R.K.; Cousins, R.J. Differential regulation of zinc transporter 1, 2, and 4 mRNA expression by dietary zinc in rats. J. Nutr. 2001, 131, 46-52.
62. El-Tanani, M.K.; Green, C.D. Insulin/IGF-1 modulation of the expression of two estrogen-induced genes in MCF-7 cells. Mol. Cell. Endocrinol. 1996, 121, 29-35.
63. Maret, W.; Krezel, A. Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Mol. Med. 2007, 13, 371-375.
64. Taylor, K.M.; Hiscox, S.; Nicholson, R.I. Zinc transporter LIV-1: A link between cellular development and cancer progression. Trends Endocrinol. Metab. 2004, 15, 461-463.
65. Ho, E. Zinc deficiency, DNA damage and cancer risk. J. Nutr. Biochem. 2004, 15, 572-578.
66. Ho, E.; Courtemanche, C.; Ames, B.N. Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. J. Nutr. 2003, 133, 2543-2548.
67. Smirnova, I.V.; Bittel, D.C.; Ravindra, R.; Jiang, H.; Andrews, G.K. Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J. Biol. Chem. 2000, 275, 9377-9384.
68. Mueller, P.R.; Salser, S.J.; Wold, B. Constitutive and metal-inducible protein:DNA interactions at the mouse metallothionein I promoter examined by in vivo and in vitro footprinting. Genes Dev. 1988, 2, 412-427.
69. LaRochelle, O.; Gagne, V.; Charron, J.; Soh, J.W.; Seguin, C. Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions. J. Biol. Chem. 2001, 276, 41879-41888.
70. Kimura, T.; Itoh, N.; Sone, T.; Kondoh, M.; Tanaka, K.; Isobe, M. Role of metal-responsive transcription factor-1 (MTF-1) in EGF-dependent DNA synthesis in primary hepatocytes. J. Cell. Biochem. 2006, 99, 485-494.
71. Miller, D.L.; el-Ashry, D.; Cheville, A.L.; Liu, Y.; McLeskey, S.W.; Kern, F.G. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ. 1994, 5, 1263-1274.
72. Kari, C.; Chan, T.O.; Rocha de Quadros, M.; Rodeck, U. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res. 2003, 63, 1-5.
73. Heuchel, R.; Radtke, F.; Georgiev, O.; Stark, G.; Aguet, M.; Schaffner, W. The transcription factor MTF-1 is essential for basal and heavy metal-induced metallothionein gene expression. EMBO J. 1994, 13, 2870-2875.
74. Klaassen, C.D.; Liu, J.; Choudhuri, S. Metallothionein: An intracellular protein to protect against cadmium toxicity. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 267-294.
75. Kang, Y.J. Metallothionein redox cycle and function. Exp. Biol. Med. (Maywood) 2006, 231, 1459-1467.
76. Achary, M.P.; Jaggernauth, W.; Gross, E.; Alfieri, A.; Klinger, H.P.; Vikram, B. Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. Cytogenet. Cell Genet. 2000, 91, 39-43.
77. Woo, E.S.; Monks, A.; Watkins, S.C.; Wang, A.S.; Lazo, J.S. Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel. Cancer Chemother. Pharmacol. 1997, 41, 61-68.
78. Aravindakumar, C.T.; Ceulemans, J.; De Ley, M. Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. Biochem. J. 1999, 344, 253-258.
79. Soltaninassab, S.R.; Sekhar, K.R.; Meredith, M.J.; Freeman, M.L. Multi-faceted regulation of gamma-glutamylcysteine synthetase. J. Cell Physiol. 2000, 182, 163-170.
80. Suzuki, K.T.; Kuroda, T. Transfer of copper and zinc from ionic and metallothionein-bound forms to Cu, Zn-superoxide dismutase. Res. Commun. Mol. Pathol. Pharmacol. 1995, 87, 287-296.
81. Barbato, J.C.; Catanescu, O.; Murray, K.; DiBello, P.M.; Jacobsen, D.W. Targeting of metallothionein by L-homocysteine: A novel mechanism for disruption of zinc and redox homeostasis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 49-54.
82. Maret, W.; Vallee, B.L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc. Natl. Acad. Sci. USA 1998, 95, 3478-3482.
83. Tamai, K.T.; Gralla, E.B.; Ellerby, L.M.; Valentine, J.S.; Thiele, D.J. Yeast and mammalian metallothioneins functionally substitute for yeast copper-zinc superoxide dismutase. Proc. Natl. Acad. Sci. USA 1993, 90, 8013-8017.
84. Li, Z.; Li, J.; Mo, B.; Hu, C.; Liu, H.; Qi, H.; Wang, X.; Xu, J. Genistein induces G(2)/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol. Toxicol. 2008, 24, 401-409.
85. Iwasaki, M.; Inoue, M.; Otani, T.; Sasazuki, S.; Kurahashi, N.; Miura, T.; Yamamoto, S.; Tsugane, S. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: A nested case-control study from the Japan Public Health Center-Based Prospective Study Group. J. Clin. Oncol. 2008, 26, 1677-1683.
86. Perabo, F.G.; Von Low, E.C.; Ellinger, J.; von Rucker, A.; Muller, S.C.; Bastian, P.J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic. Dis. 2008, 11, 6-12.
87. Chung, M.J.; Kang, A.Y.; Lee, K.M.; Oh, E.; Jun, H.J.; Kim, S.Y.; Auh, J.H.; Moon, T.W.; Lee, S.J.; Park, K.H. Water-soluble genistin glycoside isoflavones up-regulate antioxidant metallothionein expression and scavenge free radicals. J. Agric. Food Chem. 2006, 54, 3819-3826.
88. Aydin, A.; Arsova-Sarafinovska, Z.; Sayal, A.; Eken, A.; Erdem, O.; Erten, K.; Ozgok, Y.; Dimovski, A. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin. Biochem. 2006, 39, 176-179.
89. Taylor, C.G.; Bettger, W.J.; Bray, T.M. Effect of dietary zinc or copper deficiency on the primary free radical defense system in rats. J. Nutr. 1988, 118, 613-621.
90. Podmore, I.D.; Griffiths, H.R.; Herbert, K.E.; Mistry, N.; Mistry, P.; Lunec, J. Vitamin C exhibits pro-oxidant properties. Nature 1998, 392, 559.
91. Berg, J.M.; Shi, Y. The galvanization of biology: A growing appreciation for the roles of zinc. Science 1996, 271, 1081-1085.
92. Dalton, T.P.; Li, Q.; Bittel, D.; Liang, L.; Andrews, G.K. Oxidative stress activates metal-responsive transcription factor-1 binding activity. Occupancy in vivo of metal response elements in the metallothionein-I gene promoter. J. Biol. Chem. 1996, 271, 26233-26241.
93. Escarcega, R.O.; Fuentes-Alexandro, S.; Garcia-Carrasco, M.; Gatica, A.; Zamora, A. The transcription factor nuclear factor-kappa B and cancer. Clin. Oncol. (R. Coll. Radiol.) 2007, 19, 154-161.
94. Knoell, D.L.; Julian, M.W.; Bao, S.; Besecker, B.; Macre, J.E.; Leikauf, G.D.; DiSilvestro, R.A.; Crouser, E.D. Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis. Crit. Care Med. 2009, 37, 1380-1388.
95. Chung, M.J.; Walker, P.A.; Brown, R.W.; Hogstrand, C. ZINC-mediated gene expression offers protection against H2O2-induced cytotoxicity. Toxicol. Appl. Pharmacol. 2005, 205, 225-236.
96. Chung, M.J.; Hogstrand, C.; Lee, S.J. Cytotoxicity of nitric oxide is alleviated by zinc-mediated expression of antioxidant genes. Exp. Biol. Med. (Maywood) 2006, 231, 1555-1563.
97. Maret, W. Metallothionein redox biology in the cytoprotective and cytotoxic functions of zinc. Exp. Gerontol. 2008, 43, 363-369.
98. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D.A.; Goulet, R.J., Jr.; Sledge, G.W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17, 3629-3639.
99. Uzzo, R.G.; Leavis, P.; Hatch, W.; Gabai, V.L.; Dulin, N.; Zvartau, N.; Kolenko, V.M. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin. Cancer Res. 2002, 8, 3579-3583.
100. Muenchen, H.J.; Lin, D.L.; Walsh, M.A.; Keller, E.T.; Pienta, K.J. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin. Cancer Res. 2000, 6, 1969-1977.
101. Huang, S.; Pettaway, C.A.; Uehara, H.; Bucana, C.D.; Fidler, I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20, 4188-4197.
102. Uzzo, R.G.; Crispen, P.L.; Golovine, K.; Makhov, P.; Horwitz, E.M.; Kolenko, V.M. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: Implications for prostate cancer progression. Carcinogenesis 2006, 27, 1980-1990.
103. Truong-Tran, A.Q.; Ho, L.H.; Chai, F.; Zalewski, P.D. Cellular zinc fluxes and the regulation of apoptosis/gene-directed cell death. J. Nutr. 2000, 130, 1459S-1466S.
104. Oteiza, P.L.; Olin, K.L.; Fraga, C.G.; Keen, C.L. Oxidant defense systems in testes from zinc-deficient rats. Proc. Soc. Exp. Biol. Med. 1996, 213, 85-91.
105. Oteiza, P.I.; Olin, K.L.; Fraga, C.G.; Keen, C.L. Zinc deficiency causes oxidative damage to proteins, lipids and DNA in rat testes. J. Nutr. 1995, 125, 823-829.
106. Olin, K.L.; Shigenaga, M.K.; Ames, B.N.; Golub, M.S.; Gershwin, M.E.; Hendrickx, A.G.; Keen, C.L. Maternal dietary zinc influences DNA strand break and 8-hydroxy-2′-deoxyguanosine levels in infant rhesus monkey liver. Proc. Soc. Exp. Biol. Med. 1993, 203, 461-466.
107. Jones, P.A.; Laird, P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21, 163-167.
108. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat. Rev. Drug. Discov. 2006, 5, 37-50.
109. Wallwork, J.C.; Duerre, J.A. Effect of zinc deficiency on methionine metabolism, methylation reactions and protein synthesis in isolated perfused rat liver. J. Nutr. 1985, 115, 252-262.
110. Finnin, M.S.; Donigian, J.R.; Pavletich, N.P. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 2001, 8, 621-625.
111. Fatemi, M.; Hermann, A.; Pradhan, S.; Jeltsch, A. The activity of the murine DNA methyltransferase Dnmt1 is controlled by interaction of the catalytic domain with the N-terminal part of the enzyme leading to an allosteric activation of the enzyme after binding to methylated DNA. J. Mol. Biol. 2001, 309, 1189-1199.
112. Somoza, J.R.; Skene, R.J.; Katz, B.A.; Mol, C.; Ho, J.D.; Jennings, A.J.; Luong, C.; Arvai, A.; Buggy, J.J.; Chi, E.; et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
113. Zhang, X.; Tamaru, H.; Khan, S.I.; Horton, J.R.; Keefe, L.J.; Selker, E.U.; Cheng, X. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell 2002, 111, 117-127.
114. Zhou, Q.; Atadja, P.; Davidson, N.E. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 2007, 6, 64-69.
115. Roth, H.P.; Kirchgessner, M. Influence of alimentary zinc deficiency on the concentration of growth hormone (GH), insulin-like growth factor I (IGF-I) and insulin in the serum of force-fed rats. Horm. Metab. Res. 1994, 26, 404-408.
116. Giovannucci, E.; Pollak, M.; Liu, Y.; Platz, E.A.; Majeed, N.; Rimm, E.B.; Willett, W.C. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol. Biomark. Prev. 2003, 12, 84-89.
117. Lynch, C.J.; Patson, B.J.; Goodman, S.A.; Trapolsi, D.; Kimball, S.R. Zinc stimulates the activity of the insulin-and nutrient-regulated protein kinase mTOR. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E25-E34.
118. Ghayad, S.E.; Vendrell, J.A.; Ben Larbi, S.; Dumontet, C.; Bieche, I.; Cohen, P.A. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int. J. Cancer 2010, 126, 545-562.
119. Hennessy, B.T.; Lu, Y.; Poradosu, E.; Yu, Q.; Yu, S.; Hall, H.; Carey, M.S.; Ravoori, M.; Gonzalez-Angulo, A.M.; Birch, R.; et al. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res. 2007, 13, 7421-7431.
120. Leitzmann, M.F.; Stampfer, M.J.; Wu, K.; Colditz, G.A.; Willett, W.C.; Giovannucci, E.L. Zinc Supplement use and risk of prostate cancer. J. Natl. Cancer Inst. 2003, 95, 1004-1007.
121. Gonzalez, A.; Peters, U.; Lampe, J.W.; White, E. Zinc intake from supplements and diet and prostate cancer. Nutr. Cancer 2009, 61, 206-215.
122. Epstein, M.M.; Kasperzyk, J.L.; Andren, O.; Giovannucci, E.L.; Wolk, A.; Hakansson, N.; Andersson, S.O.; Johansson, J.E.; Fall, K.; Mucci, L.A. Dietary zinc and prostate cancer survival in a Swedish cohort. Am. J. Clin. Nutr. 2011, 93, 586-593.
123. Stoll, B.A. Breast cancer: Further metabolic-endocrine risk markers? Br. J. Cancer 1997, 76, 1652-1654.
124. Stattin, P.; Bylund, A.; Rinaldi, S.; Biessy, C.; Dechaud, H.; Stenman, U.H.; Egevad, L.; Riboli, E.; Hallmans, G.; Kaaks, R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl. Cancer Inst. 2000, 92, 1910-1917.
125. Palmqvist, R.; Hallmans, G.; Rinaldi, S.; Biessy, C.; Stenling, R.; Riboli, E.; Kaaks, R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in northern Sweden. Gut 2002, 50, 642-646.
126. Dupont, J.; Karas, M.; LeRoith, D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J. Biol. Chem. 2000, 275, 35893-35901.
127. Tang, H.B.; Ren, Y.P.; Zhang, J.; Ma, S.H.; Gao, F.; Wu, Y.P. Correlation of insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice (in Chinese). Ai Zheng 2007, 26, 1215-1220.
128. Shigematsu, S.; Yamauchi, K.; Nakajima, K.; Iijima, S.; Aizawa, T.; Hashizume, K. IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr. J. 1999, 46, S59-S62.
129. Kahlert, S.; Nuedling, S.; van Eickels, M.; Vetter, H.; Meyer, R.; Grohe, C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 2000, 275, 18447-18453.
130. Wan, X.; Helman, L.J. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 2002, 4, 400-408.
131. Abe, S.; Funato, T.; Takahashi, S.; Yokoyama, H.; Yamamoto, J.; Tomiya, Y.; Yamada-Fujiwara, M.; Ishizawa, K.; Kameoka, J.; Kaku, M.; et al. Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J. Exp. Med. 2006, 209, 217-228.
132. Wiseman, L.R.; Johnson, M.D.; Wakeling, A.E.; Lykkesfeldt, A.E.; May, F.E.; Westley, B.R. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer 1993, 29, 2256-2264.
133. Yap, T.A.; Olmos, D.; Molife, L.R.; de Bono, J.S. Targeting the insulin-like growth factor signaling pathway: Figitumumab and other novel anticancer strategies. Expert Opin. Investig. Drugs 2011, 20, 1293-1304.
134. Yee, D.; Paik, S.; Lebovic, G.S.; Marcus, R.R.; Favoni, R.E.; Cullen, K.J.; Lippman, M.E.; Rosen, N. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol. Endocrinol. 1989, 3, 509-517.
135. De Leon, D.D.; Wilson, D.M.; Bakker, B.; Lamsom, G.; Hintz, R.L.; Rosenfeld, R.G. Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Mol. Endocrinol. 1989, 3, 567-574.
136. Huff, K.K.; Kaufman, D.; Gabbay, K.H.; Spencer, E.M.; Lippman, M.E.; Dickson, R.B. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res. 1986, 46, 4613-4619.
137. Huff, K.K.; Knabbe, C.; Lindsey, R.; Kaufman, D.; Bronzert, D.; Lippman, M.E.; Dickson, R.B. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol. Endocrinol. 1988, 2, 200-208.
138. Yee, D.; Lee, A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5, 107-115.
139. Arteaga, C.L.; Kitten, L.J.; Coronado, E.B.; Jacobs, S.; Kull, F.C., Jr.; Allred, D.C.; Osborne, C.K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 1989, 84, 1418-1423.
140. Arteaga, C.L.; Osborne, C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989, 49, 6237-6241.
141. Om, A.S.; Chung, K.W. Dietary zinc deficiency alters 5 alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver. J. Nutr. 1996, 126, 842-848.
142. Buzdar, A.U.; Robertson, J.F. Fulvestrant: Pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann. Pharmacother. 2006, 40, 1572-1583.
143. James, V.H.; McNeill, J.M.; Lai, L.C.; Newton, C.J.; Ghilchik, M.W.; Reed, M.J. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies. Steroids 1987, 50, 269-279.
144. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
145. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. p53 mutations in human cancers. Science 1991, 253, 49-53.
146. Stefanidou, M.; Maravelias, C.; Dona, A.; Spiliopoulou, C. Zinc: A multipurpose trace element. Arch. Toxicol. 2006, 80, 1-9.
147. Cho, Y.; Gorina, S.; Jeffrey, P.D.; Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265, 346-355.
148. Harris, S.L.; Levine, A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 2005, 24, 2899-2908.
149. Li, M.; Chen, D.; Shiloh, A.; Luo, J.; Nikolaev, A.Y.; Qin, J.; Gu, W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002, 416, 648-653.
150. Pavletich, N.P.; Chambers, K.A.; Pabo, C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993, 7, 2556-2564.
151. Jeffy, B.D.; Hockings, J.K.; Kemp, M.Q.; Morgan, S.S.; Hager, J.A.; Beliakoff, J.; Whitesell, L.J.; Bowden, G.T.; Romagnolo, D.F. An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: Repressive effects of p53 on BRCA-1 transcription. Neoplasia 2005, 7, 873-882.
152. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66-71.
153. Cousineau, I.; Abaji, C.; Belmaaza, A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: Implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res. 2005, 65, 11384-11391.
154. Benzeno, S.; Narla, G.; Allina, J.; Cheng, G.Z.; Reeves, H.L.; Banck, M.S.; Odin, J.A.; Diehl, J.A.; Germain, D.; Friedman, S.L. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004, 64, 3885-3891.
155. Chen, C.; Hyytinen, E.R.; Sun, X.; Helin, H.J.; Koivisto, P.A.; Frierson, H.F., Jr.; Vessella, R.L.; Dong, J.T. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am. J. Pathol. 2003, 162, 1349-1354.
156. Kuraishy, A.; Karin, M.; Grivennikov, S.I. Tumor promotion via injury-and death-induced inflammation. Immunity 2011, 35, 467-477.
157. Lin, W.W.; Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117, 1175-1183.
158. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
159. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410, 1107-1111.
160. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331, 1565-1570.
161. Mahmoud, S.M.; Paish, E.C.; Powe, D.G.; Macmillan, R.D.; Grainge, M.J.; Lee, A.H.; Ellis, I.O.; Green, A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011, 29, 1949-1955.
162. Consolini, R.; Cei, B.; Cini, P.; Bottone, E.; Casarosa, L. Circulating thymic hormone activity in young cancer patients. Clin. Exp. Immunol. 1986, 66, 173-180.
163. Gaetke, L.M.; McClain, C.J.; Talwalkar, R.T.; Shedlofsky, S.I. Effects of endotoxin on zinc metabolism in human volunteers. Am. J. Physiol. 1997, 272, E952-E956.
164. Liuzzi, J.P.; Lichten, L.A.; Rivera, S.; Blanchard, R.K.; Aydemir, T.B.; Knutson, M.D.; Ganz, T.; Cousins, R.J. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc. Natl. Acad. Sci. USA 2005, 102, 6843-6848.
165. Mocchegiani, E.; Muzzioli, M.; Cipriano, C.; Giacconi, R. Zinc, T-cell pathways, aging: Role of metallothioneins. Mech. Ageing Dev. 1998, 106, 183-204.
166. Kitamura, H.; Morikawa, H.; Kamon, H.; Iguchi, M.; Hojyo, S.; Fukada, T.; Yamashita, S.; Kaisho, T.; Akira, S.; Murakami, M.; et al. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function. Nat. Immunol. 2006, 7, 971-977.
167. Von Bulow, V.; Rink, L.; Haase, H. Zinc-mediated inhibition of cyclic nucleotide phosphodiesterase activity and expression suppresses TNF-alpha and IL-1 beta production in monocytes by elevation of guanosine 3′,5′-cyclic monophosphate. J. Immunol. 2005, 175, 4697-4705.
168. Csermely, P.; Somogyi, J. Zinc as a possible mediator of signal transduction in T lymphocytes. Acta Physiol. Hung. 1989, 74, 195-199.
169. DePasquale-Jardieu, P.; Fraker, P.J. The role of corticosterone in the loss in immune function in the zinc-deficient A/J mouse. J. Nutr. 1979, 109, 1847-1855.
170. King, L.E.; Osati-Ashtiani, F.; Fraker, P.J. Apoptosis plays a distinct role in the loss of precursor lymphocytes during zinc deficiency in mice. J. Nutr. 2002, 132, 974-979.
171. Teschendorff, A.E.; Menon, U.; Gentry-Maharaj, A.; Ramus, S.J.; Weisenberger, D.J.; Shen, H.; Campan, M.; Noushmehr, H.; Bell, C.G.; Maxwell, A.P.; et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010, 20, 440-446.
172. Haase, H.; Rink, L. The immune system and the impact of zinc during aging. Immun. Ageing 2009, 6, 9.
173. Prasad, A.S. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J. Infect. Dis. 2000, 182, S62-S68.
174. Manning, D.L.; Daly, R.J.; Lord, P.G.; Kelly, K.F.; Green, C.D. Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 human breast cancer cell line. Mol. Cell. Endocrinol. 1988, 59, 205-212.
175. Frasor, J.; Stossi, F.; Danes, J.M.; Komm, B.; Lyttle, C.R.; Katzenellenbogen, B.S. Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004, 64, 1522-1533.
176. Taylor, K.M.; Morgan, H.E.; Smart, K.; Zahari, N.M.; Pumford, S.; Ellis, I.O.; Robertson, J.F.; Nicholson, R.I. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol. Med. 2007, 13, 396-406.
177. Manning, D.L.; Robertson, J.F.; Ellis, I.O.; Elston, C.W.; McClelland, R.A.; Gee, J.M.; Jones, R.J.; Green, C.D.; Cannon, P.; Blamey, R.W.; et al. Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement. Eur. J. Cancer 1994, 30A, 675-678.
178. Kasper, G.; Weiser, A.A.; Rump, A.; Sparbier, K.; Dahl, E.; Hartmann, A.; Wild, P.; Schwidetzky, U.; Castanos-Velez, E.; Lehmann, K. Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. Int. J. Cancer 2005, 117, 961-973.
179. Shen, H.; Qin, H.; Guo, J. Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7. Mol. Biol. Rep. 2009, 36, 653-659.
180. Kambe, T.; Andrews, G.K. Novel proteolytic processing of the ectodomain of the zinc transporter ZIP4 (SLC39A4) during zinc deficiency is inhibited by acrodermatitis enteropathica mutations. Mol. Cell Biol. 2009, 29, 129-139.
181. Curran, S.; Murray, G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189, 300-308.
182. McClelland, R.A.; Manning, D.L.; Gee, J.M.; Willsher, P.; Robertson, J.F.; Ellis, I.O.; Blamey, R.W.; Nicholson, R.I. Oestrogen-regulated genes in breast cancer: Association of pLIV1 with response to endocrine therapy. Br. J. Cancer 1998, 77, 1653-1656.
183. Manning, D.L.; McClelland, R.A.; Knowlden, J.M.; Bryant, S.; Gee, J.M.; Green, C.D.; Robertson, J.F.; Blamey, R.W.; Sutherland, R.L.; Ormandy, C.J.; et al. Differential expression of oestrogen regulated genes in breast cancer. Acta Oncol. 1995, 34, 641-646.
184. Monnier, A. FACE: The barefaced facts of AI potency. Cancer Manag. Res. 2010, 2, 267-276.
185. Levi, J.A.; Wheeler, H.R. Current status of treatment for breast cancer. Ann. Acad. Med. Singap. 1990, 19, 281-285.
186. Lee, J.Y.; Kim, J.H.; Hong, S.H.; Cherny, R.A.; Bush, A.I.; Palmiter, R.D.; Koh, J.Y. Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J. Biol. Chem. 2004, 279, 8602-8607.
187. McClelland, R.A.; Manning, D.L.; Gee, J.M.; Anderson, E.; Clarke, R.; Howell, A.; Dowsett, M.; Robertson, J.F.; Blamey, R.W.; Wakeling, A.E.; et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res. Treat. 1996, 41, 31-41.
188. Lopez, V.; Kelleher, S.L. Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. Exp. Cell Res. 2010, 316, 366-375.
189. Huang, H.J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Vergote, I.; Christiaens, M.R. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J. Clin. Pathol. 2005, 58, 611-616.
190. Berstein, L.M.; Tsyrlina, E.V.; Poroshina, T.E.; Levina, V.V.; Vasilyev, D.A.; Kovalenko, I.G.; Semiglazov, V.F. Genotoxic factors associated with the development of receptor-negative breast cancer: Potential role of the phenomenon of switching of estrogen effects. Exp. Oncol. 2006, 28, 64-69.
191. O'Lone, R.; Frith, M.C.; Karlsson, E.K.; Hansen, U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 2004, 18, 1859-1875.
192. Bjornstrom, L.; Sjoberg, M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 2005, 19, 833-842.
193. Kim, K.; Thu, N.; Saville, B.; Safe, S. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol. Endocrinol. 2003, 17, 804-817.
194. Porter, W.; Saville, B.; Hoivik, D.; Safe, S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11, 1569-1580.
195. Ariazi, E.A.; Kraus, R.J.; Farrell, M.L.; Jordan, V.C.; Mertz, J.E. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol. Cancer Res. 2007, 5, 71-85.
196. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
197. Yamashita, S.; Miyagi, C.; Fukada, T.; Kagara, N.; Che, Y.S.; Hirano, T. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004, 429, 298-302.
198. Maass, H.; Jonat, W.; Stolzenbach, G.; Trams, G. The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 1980, 46, 2835-2837.
199. Oka, H.; Shiozaki, H.; Kobayashi, K.; Inoue, M.; Tahara, H.; Kobayashi, T.; Takatsuka, Y.; Matsuyoshi, N.; Hirano, S.; Takeichi, M.; et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993, 53, 1696-1701.
200. Kowalski, P.J.; Rubin, M.A.; Kleer, C.G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003, 5, R217-R222.
201. Cano, A.; Perez-Moreno, M.A.; Rodrigo, I.; Locascio, A.; Blanco, M.J.; del Barrio, M.G.; Portillo, F.; Nieto, M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2, 76-83.
202. Lopez, V.; Kelleher, S.L. Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. Exp. Cell Res. 2010, 316, 366-375.
203. Fujita, N.; Jaye, D.L.; Kajita, M.; Geigerman, C.; Moreno, C.S.; Wade, P.A. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113, 207-219.
204. Toyama, T.; Zhang, Z.; Iwase, H.; Yamashita, H.; Ando, Y.; Hamaguchi, M.; Mizutani, M.; Kondo, N.; Fujita, T.; Fujii, Y.; et al. Low expression of the snail gene is a good prognostic factor in node-negative invasive ductal carcinomas. Jpn. J. Clin. Oncol. 2006, 36, 357-363.
205. Chen, S.; Ye, J.; Kijima, I.; Kinoshita, Y.; Zhou, D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J. Steroid Biochem. Mol. Biol. 2005, 95, 17-23.
206. el-Tanani, M.K.; Green, C.D. Interaction between estradiol and cAMP in the regulation of specific gene expression. Mol. Cell. Endocrinol. 1996, 124, 71-77.
207. Klijn, J.G.; Berns, P.M.; Bontenbal, M.; Alexieva-Figusch, J.; Foekens, J.A. Clinical breast cancer, new developments in selection and endocrine treatment of patients. J. Steroid Biochem. Mol. Biol. 1992, 43, 211-221.